Saturday 17 October 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
In the quarter to December 2025, revenue grew 948.4%, EPS fell 20.0% and free cash flow grew 4.48%, each against the same quarter a year earlier.
1.68
0.19
−10.16%
Follow MLEC
| Older periods | Jun '24 | Sep '24 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(25.13%) | (452.66%) | (709.95%) | 0.00% | |
| (6.71%) | (119.93%) | (127.71%) | 0.00% | ||
ROIC |
1.90% | 50.68% | 52.66% | 0.00% | |
Return on Tangible Assets |
(38.27%) | (656.00%) | (773.67%) | 0.00% | |
Average Days of Receivables |
191.21 | 1.27 | 2.13 | 0.00 | |
Free Cash Flow per Share |
37.87 | 72.73 | 69.80 | 0.00 | |
Free Cash Flow |
14.70 | 18.76 | 18.14 | 18.34 | |
Capital Expenditures |
(24.85) | (21.41) | (25.05) | (26.44) | |
| Other line items | |||||
Cash ROIC |
1.91% | 60.12% | 68.12% | 22.19% | |
Accounts Receivable Turnover |
3.79 | 271.64 | 237.93 | 0.00 | |
Accounts Payable Turnover |
3.17 | 53.51 | 74.50 | 0.00 | |
Inventory Turnover |
4.41 | 93.63 | 105.75 | 0.00 | |
Average Days of Payables |
220.72 | 3.50 | 4.05 | 0.00 | |
Days of Inventory on Hand |
164.91 | 7.29 | 6.26 | 0.00 | |
Tax Rate |
0.04 | 0.05 | 0.06 | — | |
Research and Development Expense of Revenue |
3.74% | 3.75% | 3.68% | — | |
Selling, General and Administrative Expense of Revenue |
27.09% | 27.03% | 26.77% | — | |
Share Based Compensation of Revenue |
3.04% | 3.02% | 2.78% | 0.00% | |
Interest Coverage |
0.51 | 0.51 | 0.50 | — | |
Operating CF/Net income |
(1.21) | (1.22) | (1.28) | 0.00 | |
Depreciation/Fixed assets |
0.24 | 14.53 | 14.32 | 4.31 | |
Capex/Depreciation |
(1.39) | (1.19) | (1.38) | (1.41) | |
Revenue per Share |
1,201.07 | 1,806.95 | 1,802.94 | — | |
Operating CF per Share |
101.87 | 155.72 | 166.18 | 0.00 | |
Capex per Share |
(64.01) | (82.99) | (96.38) | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.00 |
Columns are period end dates